Price Alert: Shares of Gamida Cell (GMDA) Trade 9.09% Higher at Midday May 13

Equities Staff  |

Today Gamida Cell Ltd (NASDAQ: GMDA) is trading 9.09% higher.

The latest price, as of 11:57:25 est, was $2.39. Gamida Cell has moved $0.2 in trading today.

305,212 shares have exchanged hands.

As of the previous close, Gamida Cell has a YTD change of 13.39%. The company anticipates its next earnings on 2022-08-10.

For technical charts, analysis, and more on Gamida Cell visit the company profile.

About Gamida Cell Ltd

Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases. The company harnesses its cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need.

To get more information on Gamida Cell Ltd and to follow the company's latest updates, you can visit the company's profile page here: Gamida Cell Ltd's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Big Lots Down 18% in Premarket Trading Friday on Surprise Missed Earnings
Modine Posts Strong Rebound in Fiscal Q4, Raises 2023 Guidance
Dollar Tree Posts Record First Quarter, Leads Nasdaq Gainers
Kohl's Still in Play To Be Acquired
Chinook Therapeutics Raises $105 Million for Kidney Disease Therapies
Market Conditions Driving Higher Base Level for VIX Volatility Index
Will New AT&T, Dish Co-opetition Deal Work: Jeff Kagan
Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast



Market Movers

Sponsored Financial Content